Cerebrolysin Research Peptide — Scientific Overview
Cerebrolysin is a standardized preparation of neuropeptides derived from purified pig brain tissue through controlled enzymatic hydrolysis. The resulting mixture consists of approximately 80% low-molecular-weight peptides (primarily below 10,000 Da) and 20% free amino acids. Cerebrolysin has been manufactured by Ever Neuro Pharma (formerly EVER Pharma, Austria) since the 1950s and has accumulated one of the most extensive clinical research records of any neuropeptide preparation, with published studies across Europe, Asia, and North America.
As a research compound, Cerebrolysin is of interest because it contains multiple bioactive neuropeptides that collectively exhibit neurotrophic, neuroprotective, and neuroregenerative properties in laboratory models. Key identified peptides within Cerebrolysin include fragments showing BDNF-like, NGF-like, and CNTF-like activities. Research has demonstrated that Cerebrolysin crosses the blood-brain barrier when administered parenterally, making it a valuable research tool for CNS-targeted neuropeptide studies.
Research Background
Cerebrolysin’s research record includes preclinical studies on Alzheimer’s disease models, stroke/ischemia models, traumatic brain injury, Parkinson’s disease models, and age-related cognitive decline. Clinical studies (including several Cochrane-reviewed randomized trials) have examined its use in vascular dementia and Alzheimer’s disease in human subjects. It is registered as a pharmaceutical in over 40 countries and is an approved pharmaceutical in parts of Europe and Asia, though not FDA-approved in the United States.
Key Research Areas
- Neuroprotective Research: Neuronal survival and protection against excitotoxicity, ischemia, and oxidative stress
- Alzheimer’s Research: Amyloid biology, tau pathology, and cognitive outcomes in AD models
- Neuroplasticity Research: Synaptic density, dendritic arborization, and LTP studies
- Neurotrophic Research: BDNF/NGF/CNTF-like activity and neurotrophic factor upregulation
- Stroke Research: Ischemia recovery and neuroprotection in cerebrovascular models
- TBI Research: Traumatic brain injury neuroprotection and neuroregeneration studies
Technical Specifications
| Parameter |
Value |
| Classification |
Standardized neuropeptide mixture (porcine brain-derived) |
| Composition |
~80% low-MW peptides + 20% free amino acids |
| Purity/QC |
Standardized preparation; COA confirms composition profile |
| Form |
Lyophilized or solution (specify at order) |
| Storage |
2–8°C (solution); −20°C (lyophilized) |
| Documentation |
Batch-specific COA with composition profile |
Storage & Handling (Research Laboratories)
Lyophilized Cerebrolysin should be stored at −20°C for long-term preservation, protected from light and moisture. For short-term active research use, 4°C storage is acceptable for up to approximately 4 weeks. Minimize repeated freeze-thaw cycles. Follow standard laboratory peptide reconstitution and handling protocols for all experimental use.
Frequently Asked Questions — Cerebrolysin Research
What is Cerebrolysin and how is it produced?
Cerebrolysin is a standardized neuropeptide preparation produced through controlled enzymatic hydrolysis of purified pig brain proteins by Ever Neuro Pharma. The process breaks brain proteins down into a consistent mixture of approximately 80% low-molecular-weight bioactive peptides and 20% free amino acids. The preparation is standardized to ensure batch-to-batch consistency in composition and biological activity. As a research compound, Cerebrolysin’s complexity (it contains hundreds of identified peptides) is both a challenge (no single defined mechanism) and an advantage (multiple pathways activated simultaneously).
How does Cerebrolysin cross the blood-brain barrier?
The low molecular weight of Cerebrolysin’s peptide components (most below 10,000 Da, many below 1,000 Da) allows them to cross the blood-brain barrier through multiple mechanisms including passive diffusion, carrier-mediated transport, and transcytosis. In vitro and in vivo studies have confirmed CNS bioavailability of Cerebrolysin peptides when administered parenterally. This blood-brain barrier penetrance distinguishes Cerebrolysin from high-molecular-weight neurotrophic proteins like BDNF and NGF that have limited CNS access.
What is the research evidence base for Cerebrolysin?
Cerebrolysin has one of the largest published evidence bases of any neuropeptide preparation, including multiple randomized controlled clinical trials. Cochrane systematic reviews have examined the evidence for Cerebrolysin in vascular dementia and Alzheimer’s disease. A 2020 Cochrane review on vascular dementia (Muresanu et al. studies) noted some cognitive benefit signals but acknowledged methodological limitations in many trials. The compound remains approved as a pharmaceutical in over 40 countries based on this evidence base, though it is not FDA-approved.
Is Cerebrolysin approved in the USA?
Cerebrolysin is not FDA-approved for use in the United States. It is approved as a pharmaceutical in numerous European and Asian countries including Austria, Germany, China, Russia, and others. In the USA, it is supplied by Research Peptides Supplies strictly for qualified laboratory and scientific research use only.
What analytical documentation comes with Cerebrolysin?
Cerebrolysin from Research Peptides Supplies comes with a batch-specific COA confirming composition profile, peptide content, amino acid content, and relevant quality parameters. The complex nature of the preparation means COA documentation focuses on composition profiling rather than single-compound purity measurement.
⚗️ Research Use Only: This product is strictly intended for qualified laboratory and scientific research use by trained professionals in appropriate laboratory settings. It is not intended for human or veterinary administration, therapeutic use, food supplement applications, or any use outside controlled research environments. Not for human consumption.
